排序方式: 共有18条查询结果,搜索用时 15 毫秒
1.
Maghzi AH Etemadifar M Shaygannejad V Saadatnia M Salehi M Hassanzadeh A 《Multiple sclerosis (Houndmills, Basingstoke, England)》2007,13(5):673-675
Conjugal multiple sclerosis (MS) is a rare form of MS in which both spouses are affected, and at least one is affected after marriage. Among 1606 definite MS patients, 1076 were in marital relationship, among whom we identified six conjugal pairs, giving the conjugal rate of 0.5%. This rate is 12.5 times higher than the estimated risk of MS for the general population (0.04%). The observed conjugal rate suggests an increased risk of developing MS for MS patients' spouses, this could be due to transmission or, more likely, to the same environmental factors shared in adult life. 相似文献
2.
Basiri K Etemadifar M Derakhshan F Ashtari F Shaygannejad V Fatehi Z Maghzi AH Fatehi F 《Acta medica Iranica》2012,50(2):97-100
None of the approved immunomodulatory drugs in adults Multiple Sclerosis (MS) patients have been officially approved for the pediatric patients and are currently used off-label in this population. In this study, we evaluated the effectiveness and tolerability of intramuscular interferon beta1-a (Avonex(?)) and subcutaneously injected interferon beta1-b (Betaferon(?)) in children with definite relapsing-remitting MS (RRMS). Thirteen patients aged younger than 16, who were recently diagnosed with definite RRMS according to the McDonald's criteria, were enrolled in this study. Six patients were treated with Avonex(?) 30 μg, intramuscularly every week, and seven patients were treated with Betaferon(?) 250 μg, subcutaneously every other day. All patients were treated with adult doses; initially interferon-beta was prescribed with half dose, and it was increased to full adult dose steadily. Eleven girls and two boys, mean (SD) age of 14.7 (1.9) years, were studied. Following nine months of using interferon-beta, nine patients (69.2%) had no relapses and the remaining four, experienced only one relapse. The mean EDSS score was decreased significantly after the study period. The present study provides reasonable data for the use of interferon-beta in Pediatric MS due to lack of short-term complications and safety. Studies with larger sample size and longer follow up duration are required to shed light on the long term impact of the interferon-beta therapy in children. 相似文献
3.
Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study 总被引:3,自引:0,他引:3
BACKGROUND: Topiramate and sodium valporate are anticonvulsants, demonstrated to be effective as monotherapy for migraine prevention in placebo-controlled trials. OBJECTIVES: To compare the relative efficacy of topiramate and sodium valporate in the prevention of migraine. PATIENTS AND METHODS: A 24-week, randomized, double-blind, crossover, clinical trial was conducted from October 2003 to September 2004. A total of 64 patients with migraine headache, aged 14 to 57 years, were randomly allocated to the 2 treatment groups. The first group received topiramate (25 mg daily increment over 1 week to 50 mg) for a total of 2 months. The second group received sodium valporate (200 mg daily increment over 1 week to 400 mg) for 2 months. Response to treatment was assessed at 0, 1, 8, 16, and 24 weeks after start of therapy. RESULTS: Topiramate appeared to be equivalent in efficacy and safety to sodium valporate. A significant decrease in duration, monthly frequency, and intensity of headache occurred in both groups. Of the 32 patients treated with sodium valporate, the mean standard deviation (SD) of monthly migraine frequency decreased from 5.4 (2.5) to 4.0 (2.8) episode per month, headache intensity from 7.7 (1.2) to 5.8 (1.7) by visual analog scale (VAS), and headache duration from 21.3 (14.6) to 12.3 (10.7) hours (P < .001). Correspondingly, in the 32 patients treated with topiramate, the mean SD of monthly headache frequency decreased from 5.4 (2.0) to 3.2 (1.9) per month, headache intensity from 6.9 (1.2) to 3.7 (1.3), and headache duration from 17.3 (8.4) to 3.9 (2.7) hours (P < .001). CONCLUSION: This study demonstrates that treatment with topiramate and sodium valporate both significantly reduce migraine headache. This effect of topiramate and sodium valporate has previously been shown to reduce migraine headache, and we postulate that treatment with topiramate and sodium valporate may have a similar benefit. 相似文献
4.
Amin Ziaei Marta GarciaMiralles Carola I. Radulescu Harwin Sidik Aymeric Silvin HanGyu Bae Carine Bonnard Nur Amirah Binte Mohammad Yusof Costanza Ferrari Bardile Liang Juin Tan Alvin Yu Jin Ng Sumanty Tohari Leila Dehghani Lily Henry Xin Yi Yeo Sejin Lee Byrappa Venkatesh Sarah R. Langley Vahid Shaygannejad Bruno Reversade Sangyong Jung Florent Ginhoux Mahmoud A. Pouladi 《Brain pathology (Zurich, Switzerland)》2022,32(5)
Ermin is an actin‐binding protein found almost exclusively in the central nervous system (CNS) as a component of myelin sheaths. Although Ermin has been predicted to play a role in the formation and stability of myelin sheaths, this has not been directly examined in vivo. Here, we show that Ermin is essential for myelin sheath integrity and normal saltatory conduction. Loss of Ermin in mice caused de‐compacted and fragmented myelin sheaths and led to slower conduction along with progressive neurological deficits. RNA sequencing of the corpus callosum, the largest white matter structure in the CNS, pointed to inflammatory activation in aged Ermin‐deficient mice, which was corroborated by increased levels of microgliosis and astrogliosis. The inflammatory milieu and myelin abnormalities were further associated with increased susceptibility to immune‐mediated demyelination insult in Ermin knockout mice. Supporting a possible role of Ermin deficiency in inflammatory white matter disorders, a rare inactivating mutation in the ERMN gene was identified in multiple sclerosis patients. Our findings demonstrate a critical role for Ermin in maintaining myelin integrity. Given its near‐exclusive expression in myelinating oligodendrocytes, Ermin deficiency represents a compelling “inside‐out” model of inflammatory dysmyelination and may offer a new paradigm for the development of myelin stability‐targeted therapies. 相似文献
5.
6.
7.
Nasrin Zare Sayyed Hamid Zarkesh-Esfahani Marjan Gharagozloo Vahid Shaygannejad 《Journal of Korean medical science》2013,28(12):1801-1806
Treatment with interferon beta (IFN-β) induces the production of binding antibodies (BAbs) and neutralizing antibodies (NAbs) in patients with multiple sclerosis (MS). NAbs against IFN-β are associated with a loss of IFN-β bioactivity and decreased clinical efficacy of the drug. The objective of this study was to evaluate the incidence and the prevalence of binding antibodies (BAbs) and neutralizing antibodies (NAbs) to IFN-β in MS patients receiving CinnoVex, Rebif, or Betaferon. The presence of BAbs was studied in serum samples from 124 MS patients using one of these IFN-β medications by ELISA. The NAbs against IFN-β were measured in BAb-positive MS patients receiving IFN-β using an MxA gene expression assay (real-time RT-PCR). Of the 124 patients, 36 (29.03%) had BAbs after at least 12 months of IFN-β treatment. The proportion of BAb+ was 38.1% for Betaferon, 21.9% for Rebif, and 26.8% for CinnoVex. Five BAb-positive MS patients were lost to follow-up; thus 31 BAb-positive MS patients were studied for NAbs. NAbs were present in 25 (80.6%) of BAb-positive MS patients receiving IFN-β. In conclusion, the three IFN-β preparations have different degrees of immunogenicity. 相似文献
8.
Akbarian Fahimeh Tabatabaiefar Mohammad Amin Shaygannejad Vahid Shahpouri Mohammad Mahdi Badihian Negin Sajjadi Roshanak Dabiri Arezou Jalilian Nazanin Noori-Daloii Mohammad Reza 《Metabolic brain disease》2020,35(8):1309-1316
Metabolic Brain Disease - Various genetic and epigenetic mechanisms have been suggested to play roles as the underlying pathophysiology of Multiple Sclerosis (MS). Changes in different parts of the... 相似文献
9.
Hughes S Spelman T Trojano M Lugaresi A Izquierdo G Grand'maison F Duquette P Girard M Grammond P Oreja-Guevara C Hupperts R Boz C Bergamaschi R Giuliani G Rio ME Lechner-Scott J van Pesch V Iuliano G Fiol M Verheul F Barnett M Slee M Herbert J Kister I Vella N Moore F Petkovska-Boskova T Shaygannejad V Jokubaitis V McDonnell G Hawkins S Kee F Gray O Butzkueven H;MSBase Study Group 《Journal of neurology, neurosurgery, and psychiatry》2012,83(3):305-310
10.
Shervin Badihian Navid Manouchehri Omid Mirmosayyeb Fereshteh Ashtari Vahid Shaygannejad 《Revue neurologique》2018,174(10):716-721